Actively Recruiting
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair
Led by AbbVie · Updated on 2026-05-13
200
Participants Needed
6
Research Sites
221 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A ventral hernia happens when the muscles in the front of your belly become weak and let organs push through, causing a bulge. If it gets worse, intestines can slip into the bulge, leading to serious pain and health problems. This study aims to asses if AGN-151607-DP is safe and effective for closing the belly wall after open ventral hernia surgery, without needing a complex procedure. Adverse Events and change in disease activity will be assessed. AGN-151607-DP is an investigational drug being developed to treat ventral hernia. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 200 adult participants with midline ventral hernia needing open surgical repair will be enrolled in approximately 30 sites in the United States. Participants will receive intramuscular injections of AGN-161607-DP or matching placebo on Day 1. Duration of the study is approximately 25 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
CONDITIONS
Official Title
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Midline ventral hernia requiring open surgical repair.
You will not qualify if you...
- Medical conditions that increase risk with AGN-151607-DP, including diagnosed muscular dystrophy (such as Duchenne's muscular dystrophy), myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, mitochondrial disease, or other significant neuromuscular disorders.
- History of abdominal or hernia repair surgery requiring hospitalization within 6 months before screening.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
CARI Clinical Trials INC /ID# 278844
Riverside, California, United States, 92504
Actively Recruiting
2
University of Florida - Jacksonville /ID# 261992
Jacksonville, Florida, United States, 32209
Actively Recruiting
3
Medical Research Center /ID# 278680
Miami, Florida, United States, 33144
Actively Recruiting
4
NorthShore University-Endeavor Health Evanston Hospital /ID# 277995
Evanston, Illinois, United States, 60201
Actively Recruiting
5
Novant Health New Hanover Regional Medical Center /ID# 261979
Wilmington, North Carolina, United States, 28401-7407
Actively Recruiting
6
NextStage Clinical Research-Evergreen Surgical /ID# 278710
Eau Claire, Wisconsin, United States, 54701
Actively Recruiting
Research Team
A
ABBVIE CALL CENTER
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here